Endo Inc. Announces Launch of FDA-Approved ADRENALIN® 8 mg/250 mL Premixed Bag, Expanding Ready-to-Use Epinephrine Line

Reuters

May 16, 2025

Endo Inc. Announces Launch of FDA-Approved ADRENALIN® 8 mg/250 mL Premixed Bag, Expanding Ready-to-Use Epinephrine Line

Endo Inc. has announced the launch of its new ADRENALIN® (epinephrine in 0.9% sodium chloride injection) 8 mg/250 mL premixed bag, which is the first FDA-approved and currently the only commercially available manufacturer-prepared epinephrine premixed IV bag. The product, which will begin shipping the week of May 19, 2025, aims to support healthcare providers by reducing complexity and streamlining operations in hospitals through its ready-to-use format. Endo Inc. also plans to offer additional concentrations in the future, expanding their TruDelivery® portfolio. No grant or funding from multiple organizations was mentioned in this announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endo Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH89493) on May 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2535180821"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535180821\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535180821?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-16 04:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535180821","market":"us","top_or_hot":-1,"title":"Endo Inc. Announces Launch of FDA-Approved ADRENALIN® 8 mg/250 mL Premixed Bag, Expanding Ready-to-Use Epinephrine Line","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Endo Inc. Announces Launch of FDA-Approved ADRENALIN® 8 mg/250 mL Premixed Bag, Expanding Ready-to-Use Epinephrine Line\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Endo Inc. has announced the launch of its new ADRENALIN® (epinephrine in 0.9% sodium chloride injection) 8 mg/250 mL premixed bag, which is the first FDA-approved and currently the only commercially available manufacturer-prepared epinephrine premixed IV bag. The product, which will begin shipping the week of May 19, 2025, aims to support healthcare providers by reducing complexity and streamlining operations in hospitals through its ready-to-use format. Endo Inc. also plans to offer additional concentrations in the future, expanding their TruDelivery® portfolio. No grant or funding from multiple organizations was mentioned in this announcement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endo Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH89493) on May 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Endo Inc. Announces Launch of FDA-Approved ADRENALIN® 8 mg/250 mL Premixed Bag, Expanding Ready-to-Use Epinephrine Line</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEndo Inc. Announces Launch of FDA-Approved ADRENALIN® 8 mg/250 mL Premixed Bag, Expanding Ready-to-Use Epinephrine Line\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-16 04:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Endo Inc. Announces Launch of FDA-Approved ADRENALIN® 8 mg/250 mL Premixed Bag, Expanding Ready-to-Use Epinephrine Line\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Endo Inc. has announced the launch of its new ADRENALIN® (epinephrine in 0.9% sodium chloride injection) 8 mg/250 mL premixed bag, which is the first FDA-approved and currently the only commercially available manufacturer-prepared epinephrine premixed IV bag. The product, which will begin shipping the week of May 19, 2025, aims to support healthcare providers by reducing complexity and streamlining operations in hospitals through its ready-to-use format. Endo Inc. also plans to offer additional concentrations in the future, expanding their TruDelivery® portfolio. No grant or funding from multiple organizations was mentioned in this announcement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endo Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH89493) on May 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDL3ktHsg:1","article_id":"2535180821","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535180821","pubTimestamp":1747341419,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Endo Inc. has announced the launch of its new ADRENALIN  8 mg/250 mL premixed bag, which is the first FDA-approved and currently the only commercially available manufacturer-prepared epinephrine premixed IV bag. The product, which will begin shipping the week of May 19, 2025, aims to support healthcare providers by reducing complexity and streamlining operations in hospitals through its ready-to-use format. Endo Inc. also plans to offer additional concentrations in the future, expanding their TruDelivery portfolio. No grant or funding from multiple organizations was mentioned in this announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endo Inc. published the original content used to generate this news brief via PR Newswire  on","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NDOI":"Endo, Inc."},"translate_title":"Endo Inc.宣布推出FDA批准的肾上腺素®8 mg/250 mL预混袋，扩大即用型肾上腺素产品线","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDOI":0.9},"content_text":"Endo Inc. Announces Launch of FDA-Approved ADRENALIN® 8 mg/250 mL Premixed Bag, Expanding Ready-to-Use Epinephrine Line\n    \n\n        Endo Inc. has announced the launch of its new ADRENALIN® (epinephrine in 0.9% sodium chloride injection) 8 mg/250 mL premixed bag, which is the first FDA-approved and currently the only commercially available manufacturer-prepared epinephrine premixed IV bag. The product, which will begin shipping the week of May 19, 2025, aims to support healthcare providers by reducing complexity and streamlining operations in hospitals through its ready-to-use format. Endo Inc. also plans to offer additional concentrations in the future, expanding their TruDelivery® portfolio. No grant or funding from multiple organizations was mentioned in this announcement.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endo Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH89493) on May 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}